Top

Published in:

01-06-2014 | Original Research

Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer

Authors: Elizabeth Handorf, Nicole Crumpler, Laura Gross, Veda N. Giri

Published in: Journal of Genetic Counseling | Issue 3/2014

Abstract

HOXB13 (G84E) was reported to significantly increase risk for prostate cancer. The goal of the current analysis was to assess the prevalence of G84E in ethnically-diverse high-risk men undergoing prostate cancer screening and place the carrier frequency within the context of prevalence estimates from reported studies to gain insight into the future role of this mutation in genetic counseling. PRAP is a prostate cancer screening program for unaffected men ages 35–69 with a family history of prostate cancer or African descent. HOXB13 G84E was genotyped by pyrosequencing in 649 PRAP participants with available DNA. Prevalence of the mutation was calculated for PRAP and for reported studies and exact binomial confidence intervals were generated. Prevalence of the G84E mutation in non-African PRAP men was 0.73 %. When placed in context of the literature, this was higher than reported controls. One G84E mutation carrier was notably of Hispanic background. While the HOXB13 G84E mutation may be rare, there may be a future role in genetic testing for this mutation after further studies of clinical utility in assessing prostate cancer risk.

Akbari, M. R., Trachtenberg, J., Lee, J., Tam, S., Bristow, R., Loblaw, A., et al. (2012). Association between germline HOXB13 G84E mutation and risk of prostate cancer. Journal of the National Cancer Institute, 104(16), 1260–1262.PubMedCrossRef

Bigler SA, Pound CR, Zhou X. (2011). A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer. doi:10.1155/2011/239460.

Brandt, A., Bermejo, J. L., Sundquist, J., & Hemminki, K. (2009). Age at diagnosis and age at death in familial prostate cancer. The Oncologist, 14(12), 1209–1217.PubMedCrossRef

Breast Cancer Linkage Consortium (BCLC. (1999). Cancer risks in BRCA2 mutation carriers. Journal of the National Cancer Institute, 91, 1310–1316.CrossRef

Cancer Facts & Figures (2013) Atlanta, GA: American Cancer Society; 2013; [cited 2013 May 29]; Available from: http://www.cancer.org/research/cancerfactsfigures/index.

Catalona, W. J., Antenor, J. A., Roehl, K. A., & Moul, J. W. (2002). Screening for prostate cancer in high risk populations. The Journal of Urology, 168(5), 1980–1983. discussion 3–4.PubMedCrossRef

Chen, Z., Greenwood, C., Isaacs, W. B., Foulkes, W. D., Sun, J., Zheng, S. L., et al. (2013). The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis, 34(6), 1260–1264.PubMedCrossRef

Clopper, C. J., & Pearson, E. S. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika, 26, 404–413.CrossRef

Cybulski, C., Wokolorczyk, D., Kluzniak, W., Kashyap, A., Golab, A., Slojewski, M., et al. (2013). A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. British Journal of Cancer, 108(12), 2601–2609.PubMedCrossRef

Eeles, R. A., Olama, A. A., Benlloch, S., Saunders, E. J., Leongamornlert, D. A., Tymrakiewicz, M., et al. (2013). Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 45(4), 385–391. 91e1-2.PubMedCrossRef

Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., et al. (2012). Germline mutations in HOXB13 and prostate-cancer risk. The New England Journal of Medicine, 366(2), 141–149.PubMedCentralPubMedCrossRef

Ford, D., Easton, D. F., Bishop, D. T., Narod, S. A., & Goldgar, D. E. (1994). Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet, 343(8899), 692–695.PubMedCrossRef

Giri, V. N., Beebe-Dimmer, J., Buyyounouski, M., Konski, A., Feigenberg, S. J., Uzzo, R. G., et al. (2007). Prostate cancer risk assessment program: a 10-year update of cancer detection. The Journal of Urology, 178(5), 1920–1924. discussion 4.PubMedCrossRef

Hemminki, K., Sundquist, J., & Brandt, A. (2011). Familial mortality and familial incidence in cancer. Journal of Clinical Oncology, 29(6), 712–718.PubMedCrossRef

Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., et al. (2009). Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proceedings of the National Academy of Sciences of the United States of America, 106(23), 9362–9367.PubMedCentralPubMedCrossRef

Karlsson, R., Aly, M., Clements, M., Zheng, L., Adolfsson, J., Xu, J., et al. (2012). A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk. European Urology. doi:10.1016/j.eururo.2012.07.027.PubMed

Kicinski, M., Vangronsveld, J., & Nawrot, T. S. (2011). An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PloS One, 6(10), e27130. PMCID: 3205054.PubMedCentralPubMedCrossRef

Kluzniak, W., Wokolorczyk, D., Kashyap, A., Jakubowska, A., Gronwald, J., Huzarski, T., et al. (2013). The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. The Prostate, 73(5), 542–548.PubMedCrossRef

Laitinen, V. H., Wahlfors, T., Saaristo, L., Rantapero, T., Pelttari, L. M., Kilpivaara, O., et al. (2013). HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 22(3), 452–460.PubMedCrossRef

Liede, A., Karlan, B. Y., & Narod, S. A. (2004). Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. Journal of Clinical Oncology, 22(4), 735–742.PubMedCrossRef

Pomerantz, M., & Freedman, M. L. (2013). Clinical uncertainty of prostate cancer genetic risk panels. Science Translational Medicine, 5(182), 182ed6.PubMedCrossRef

Powell, I. J., Bock, C. H., Ruterbusch, J. J., & Sakr, W. (2010). Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. The Journal of Urology, 183(5), 1792–1796.PubMedCrossRef

Schroeck, F. R., Zuhlke, K. A., Siddiqui, J., Siddiqui, R., Cooney, K. A., & Wei, J. T. (2013). Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy. The Journal of Urology, 189(3), 849–853.PubMedCrossRef

Stott-Miller, M., Karyadi, D. M., Smith, T., Kwon, E. M., Kolb, S., Stanford, J. L., et al. (2013). HOXB13 mutations in a population-based, case–control study of prostate cancer. The Prostate, 73(6), 634–641.PubMedCentralPubMedCrossRef

Witte, J. S., Mefford, J., Plummer, S. J., Liu, J., Cheng, I., Klein, E. A., et al. (2013). HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiology, Biomarkers and Prevention, 22(4), 675–680.PubMedCentralPubMedCrossRef

Xu, J., Lange, E. M., Lu, L., Zheng, S. L., Wang, Z., et al. (2013). HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Human Genetics, 132(1), 5–14.PubMedCentralPubMedCrossRef

Zeegers, M. P., Jellema, A., & Ostrer, H. (2003). Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer, 97(8), 1894–1903.PubMedCrossRef

Zuhlke, K. A., Madeoy, J. J., Beebe-Dimmer, J., White, K. A., Griffin, A., Lange, E. M., et al. (2004). Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Clinical Cancer Research, 10(18 Pt 1), 5975–5980.PubMedCrossRef

Title: Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer
Authors: Elizabeth Handorf
Nicole Crumpler
Laura Gross
Veda N. Giri
Publication date: 01-06-2014
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 3/2014
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-013-9672-5

At a glance: The STEP trials

Springer Medicine

Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Genetic Counselors’ Experience with Cell-Free Fetal DNA Testing as a Prenatal Screening Option for Aneuploidy

An Exploration of the Experience of Huntington’s Disease in Family Dyads: An Interpretative Phenomenological Analysis

Seeking Balance: Decision Support Needs of Women Without Cancer and a Deleterious BRCA1 or BRCA2 Mutation

Informing Children of Their Newborn Screening Carrier Result for Sickle Cell or Cystic Fibrosis: Qualitative Study of Parents’ Intentions, Views and Support Needs

The Value of a Genetic Counselor: Improving Identification of Cancer Genetic Counseling Patients with Chart Review

Looking Back and Moving Forward: An Historical Perspective from Laboratory Genetic Counselors